來凱醫藥-B現漲超5% 此前宣佈與禮來達成全球臨牀合作協議

新浪港股

2024-12-19

熱點欄目自選股數據中心行情中心資金流向模擬交易

客戶端

　　來凱醫藥-B（02105）盤中漲超13%，截至發稿，股價上漲5.12%，現報10.06港元，成交額1.115億港元。

　　今年11月，來凱醫藥發佈公告稱，公司與禮來達成全球臨牀合作協議，禮來將負責在美國開展一項針對來凱減肥藥LAE102的Ⅰ期臨牀研究，並承擔相關費用。

　　長城證券此前指出，以增肌減脂藥物LAE102爲代表的自研管線具備良好創新前景，看好公司產品未來商業化發展。

海量資訊、精準解讀，盡在新浪財經APP

責任編輯：盧昱君

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492157192"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492157192\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492157192?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2024-12-19 11:49","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2492157192","market":"other","top_or_hot":-1,"title":"來凱醫藥-B現漲超5% 此前宣佈與禮來達成全球臨牀合作協議","media":"新浪港股","content":"<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/02105.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<a href=\"https://laohu8.com/S/02105\">來凱醫藥-B</a>（02105）盤中漲超13%，截至發稿，股價上漲5.12%，現報10.06港元，成交額1.115億港元。</p>\n<p>　　今年11月，來凱醫藥發佈公告稱，公司與<a href=\"https://laohu8.com/S/LLY\">禮來</a>達成全球臨牀合作協議，禮來將負責在美國開展一項針對來凱減肥藥LAE102的Ⅰ期臨牀研究，並承擔相關費用。</p>\n<p>　　<a href=\"https://laohu8.com/S/002939\">長城證券</a>此前指出，以增肌減脂藥物LAE102爲代表的自研管線具備良好創新前景，看好公司產品未來商業化發展。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>來凱醫藥-B現漲超5% 此前宣佈與禮來達成全球臨牀合作協議</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n來凱醫藥-B現漲超5% 此前宣佈與禮來達成全球臨牀合作協議\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">新浪港股</strong><span class=\"h-time small\">2024-12-19 11:49</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<div>\n<img src=\"http://image.sinajs.cn/n/hk/min/640x360xxfhd/02105.png\"/>\n</div>\n<div>\n<div>\n<span>熱點欄目</span>\n<s></s>\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n</div>\n客戶端\n</div>\n</div>\n<p>　　<a href=\"https://laohu8.com/S/02105\">來凱醫藥-B</a>（02105）盤中漲超13%，截至發稿，股價上漲5.12%，現報10.06港元，成交額1.115億港元。</p>\n<p>　　今年11月，來凱醫藥發佈公告稱，公司與<a href=\"https://laohu8.com/S/LLY\">禮來</a>達成全球臨牀合作協議，禮來將負責在美國開展一項針對來凱減肥藥LAE102的Ⅰ期臨牀研究，並承擔相關費用。</p>\n<p>　　<a href=\"https://laohu8.com/S/002939\">長城證券</a>此前指出，以增肌減脂藥物LAE102爲代表的自研管線具備良好創新前景，看好公司產品未來商業化發展。</p>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n<p>責任編輯：盧昱君 </p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-19/doc-inczyhfz7039680.shtml\">新浪港股</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999013999.USD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-12-19/doc-inczyhfz7039680.shtml","article_id":"2492157192","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492157192","pubTimestamp":1734580140,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　來凱醫藥-B（02105）盤中漲超13%，截至發稿，股價上漲5.12%，現報10.06港元，成交額1.115億港元。\n　　今年11月，來凱醫藥發佈公告稱，公司與禮來達成全球臨牀合作協議，禮來將負責在美國開展一項針對來凱減肥藥LAE102的Ⅰ期臨牀研究，並承擔相關費用。\n　　長城證券此前指出，以增肌減脂藥物LAE102為代表的自研管線具備良好創新前景，看好公司產品未來商業化發展。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LLY":"礼来","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","02105":"来凯医药-B","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0079474960.USD":"联博美国增长基金A","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4516":"特朗普概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2063271972.USD":"富兰克林创新领域基金","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","SG9999014906.USD":"大华全球优质成长基金Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"Laikai Pharmaceutical-B is now up more than 5%, previously announcing a global clinical cooperation agreement with Eli Lilly","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1,"LLY":1},"content_text":"熱點欄目\n\n自選股\n數據中心\n行情中心\n資金流向\n模擬交易\n\n客户端\n\n\n　　來凱醫藥-B（02105）盤中漲超13%，截至發稿，股價上漲5.12%，現報10.06港元，成交額1.115億港元。\n　　今年11月，來凱醫藥發佈公告稱，公司與禮來達成全球臨牀合作協議，禮來將負責在美國開展一項針對來凱減肥藥LAE102的Ⅰ期臨牀研究，並承擔相關費用。\n　　長城證券此前指出，以增肌減脂藥物LAE102為代表的自研管線具備良好創新前景，看好公司產品未來商業化發展。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP\n\n責任編輯：盧昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0}}}